ストックスクリーナーアプリを入手
59.43
6.33%
3.54
アフターアワーズ：
59.43
前日終値:
$55.89
開ける：
$54.34
24時間の取引高:
3.55M
Relative Volume:
2.20
時価総額：
$11.34B
収益：
$2.75B
当期純損益:
$322.29M
株価収益率:
35.59
EPS:
1.67
ネットキャッシュフロー:
$300.88M
1週間 パフォーマンス:
-13.01%
1か月 パフォーマンス:
-17.72%
6か月 パフォーマンス:
-14.86%
1年 パフォーマンス:
-33.21%
1日の値動き範囲:
$52.93
$59.88
1週間の範囲:
$52.93
$68.54
52週間の値動き範囲:
$52.93
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
名前
Biomarin Pharmaceutical Inc
セクター
電話
(415) 506-6700
住所
105 DIGITAL DRIVE, NOVATO, CA
BMRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
59.43 | 11.34B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.30 | 123.99B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.72 | 63.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
564.13 | 34.41B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.27 | 31.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
94.14 | 22.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-24 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-30 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-20 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 開始されました | Evercore ISI | Outperform |
| 2023-11-15 | 開始されました | Wells Fargo | Overweight |
| 2023-10-23 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 開始されました | Raymond James | Mkt Perform |
| 2023-09-18 | 開始されました | UBS | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2023-02-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 開始されました | Citigroup | Neutral |
| 2023-01-30 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2022-10-31 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 再開されました | Wedbush | Neutral |
| 2022-04-25 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-09 | アップグレード | Stifel | Hold → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-04 | 再開されました | Guggenheim | Buy |
| 2021-03-01 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-08-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-08-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | ダウングレード | Stifel | Buy → Hold |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 繰り返されました | Citigroup | Buy |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-24 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-04-09 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 繰り返されました | Stifel | Buy |
| 2018-08-03 | 繰り返されました | Stifel | Buy |
すべてを表示
Biomarin Pharmaceutical Inc (BMRN) 最新ニュース
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On - TradingView
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 - Yahoo Finance
What Makes BioMarin (BMRN) a New Buy Stock - Yahoo Finance
BMRN vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
BMRN stock touches 52-week low at $60.63 amid market shifts - Investing.com Canada
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study - MSN
BioMarin succeeds in trial for its metabolic disorder treatment - MSN
BMRN stock touches 52-week low at $60.63 amid market shifts By Investing.com - Investing.com South Africa
Edmond DE Rothschild Holding S.A. Boosts Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion (BMRN) - Seeking Alpha
Nomura Asset Management Co. Ltd. Sells 73,310 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint - Yahoo Finance
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin (BMRN) Advances PALYNZIQ in Key Late-Stage Trial for PK - GuruFocus
BioMarin’s PALYNZIQ shows promise for adolescents with PKU - Investing.com India
BioMarin’s PALYNZIQ shows promise for adolescents with PKU By Investing.com - Investing.com South Africa
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients - Benzinga
BioMarin's Trial for Phenylketonuria Shows Palynziq Reduces Blood Phenylalanine in Adolescents - MarketScreener
Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now? - Insider Monkey
Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales - MSN
Breakthrough: PALYNZIQ Shows Powerful Results in Teen PKU Patients, Opening New Market - Stock Titan
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
US FDA approves Sanofi's bleeding disorder therapy - MarketScreener
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance
Is BioMarin Pharmaceutical Inc. (BMRN) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Lifted by Sector Gamma AS - MarketBeat
Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharm - GuruFocus
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) - Yahoo Finance
BioMarin pharmaceutical CAO Erin Burkhart sells $92,618 in stock By Investing.com - Investing.com Australia
BioMarin pharmaceutical CAO Erin Burkhart sells $92,618 in stock - Investing.com India
Citi maintains Neutral on BioMarin stock, price target at $82 - Investing.com
BioMarin Pharmaceutical (BMRN): Among Paul Singer’s Latest Portfolio’s Top Stock Picks - Insider Monkey
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) - PR Newswire
BioMarin's VOXZOGO Achieves Breakthrough Safety Milestone in Toddlers with Dwarfism - Stock Titan
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now? - Yahoo Finance
Is BioMarin Pharmaceutical (BMRN) the Best Biotech Stock According to Billionaires? - Yahoo Finance
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why - TradingView
Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to Trade - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Biomarin Pharmaceutical Inc (BMRN) 財務データ
収益
当期純利益
現金流量
EPS
4.73%
1.48%
大文字化:
|
ボリューム (24 時間):